Rheumatoid Arthritis

Fillmore has examined the systemic complications and therapeutic outcomes associated with rheumatoid arthritis, particularly regarding the use of tumor necrosis factor inhibitors. His research indicates that these medications may offer neuroprotective benefits, significantly reducing the long-term risk of dementia and Alzheimer disease. Additionally, he has analyzed the susceptibility of patients with rheumatoid arthritis to severe COVID-19, finding that while these patients remain at risk despite vaccination, their outcomes are generally more favorable than those of solid organ transplant recipients.